iShares Biotechnology ETF
IBB
IBB
852 hedge funds and large institutions have $7.1B invested in iShares Biotechnology ETF in 2021 Q3 according to their latest regulatory filings, with 71 funds opening new positions, 239 increasing their positions, 292 reducing their positions, and 64 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less ownership
Funds ownership: →
7% less capital invested
Capital invested by funds: $7.65B → $7.1B (-$557M)
18% less repeat investments, than reductions
Existing positions increased: 239 | Existing positions reduced: 292
38% less funds holding in top 10
Funds holding in top 10: 13 → 8 (-5)
Holders
852
Holding in Top 10
8
Calls
$456M
Puts
$447M
Top Buyers
| 1 | +$67M | |
| 2 | +$66.3M | |
| 3 | +$49.4M | |
| 4 |
Goldman Sachs
New York
|
+$46.2M |
| 5 |
JP Morgan Chase
New York
|
+$42M |
Top Sellers
| 1 | -$164M | |
| 2 | -$99.3M | |
| 3 | -$87.5M | |
| 4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$81.2M |
| 5 |
Millennium Management
New York
|
-$65.9M |